Breadcrumb

  1. Home
  2. Initiatives
  3. COVID-19 Information for Health Centers and Partners
  4. HRSA Health Center COVID-19 Therapeutics Program

HRSA Health Center COVID-19 Therapeutics Program

The Biden-Harris Administration is committed to ensuring our nation's underserved communities and those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 treatments, such as oral antiviral pills.

HRSA, in partnership with HHS partners, launched a program to directly allocate a limited supply of several oral antiviral pills for the outpatient treatment of mild to moderate COVID-19 to select HRSA-supported health centers. The federal government secured a supply of these medications for distribution to the U.S. population following the issuance of Emergency Use Authorizations from the FDA.

This program supplements state/jurisdictional allocations and aims to ensure equitable access by providing an additional supply directly to HRSA-supported health centers.

Health Center Selections

The program began incrementally at approximately 200 select health centers that have pharmacy capacity and specialize in caring for particularly underserved and disproportionately affected populations (e.g., serve a significant number of people experiencing homelessness, migratory/seasonal agricultural workers, residents of public housing, people 65 and older, and those with limited English proficiency), or which have reported significant COVID-19 testing activity in the biweekly Health Center COVID-19 Survey.

On Monday, March 7, the program expanded its reach by doubling the number of health centers invited to participate to over 400. This expansion will further increase geographic representation and access to health centers serving rural communities and low-income and minority patients. As supply increases, HHS and HRSA plan to expand the program to additional health centers in the coming months.

Date Last Reviewed: